Tengjun Biotechnology Corp.
TJBHOTCConsumer Defensive
$2.00
+$0.00(+0.00%)
Market Cap$201422000
P/E Ratio—
52W High$2
52W Low$2
Tengjun Biotechnology Corp. (TJBH) · Income Statement
Annual, quarterly, or TTM views · SEC 10-K & 10-Q via FMP · adjust period and M/B/T below.
FMP · TJBH · as of 2026-06-09
Financial statements
Revenue · Gross Profit · Net Income
| Breakdown | 2022-12 | 2021-12 | 2020-12 | 2019-12 | 2018-12 |
|---|---|---|---|---|---|
| Revenue | |||||
| Revenue | $0.15B | $0.00B | $0.00B | $0.00B | $0.00B |
| Cost of Revenue | $0.01B | $0.00B | $0.00B | $0.00B | $0.00B |
| Gross Profit | $0.14B | ($0.00B) | ($0.00B) | $0.00B | $0.00B |
| Gross Margin %(computed) | 93.52% | — | — | — | — |
| Operating Expenses | |||||
| R&D Expenses | $0.00B | $0.00B | $0.00B | $0.00B | $0.00B |
| G&A Expenses | $0.00B | $0.00B | $0.00B | $0.00B | $0.00B |
| Total Operating Expenses | $0.12B | $0.00B | $0.00B | $0.00B | $0.00B |
| Operating Income | $0.02B | ($0.00B) | ($0.00B) | ($0.00B) | ($0.00B) |
| Operating Margin %(computed) | 10.70% | — | — | — | — |
| Interest Income | $0.00B | $0.00B | $0.00B | $0.00B | $0.00B |
| Interest Expense | $0.00B | $0.00B | $0.00B | $0.00B | $0.00B |
| Income Before Tax | $0.02B | ($0.00B) | ($0.00B) | ($0.00B) | ($0.00B) |
| Income Tax Expense | $0.00B | $0.00B | $0.00B | $0.00B | $0.00B |
| Net Income | $0.01B | ($0.00B) | ($0.00B) | ($0.00B) | ($0.00B) |
| Net Margin %(computed) | 7.56% | — | — | — | — |
| Per Share & EBITDA | |||||
| EPS (Basic) | $0.14 | $-0.01 | $-0.00 | $-0.00 | $-0.00 |
| Wtd Avg Shares | 0.08B | 0.06B | 0.06B | 0.04B | 0.04B |
| EBITDA | $0.02B | ($0.00B) | ($0.00B) | $0.00B | ($0.00B) |
| EBITDA Margin %(computed) | 10.91% | — | — | — | — |
Data source: Financial Modeling Prep · Last updated: 2026-06-09 · USD · B
Explore more Tengjun Biotechnology Corp. data
About Tengjun Biotechnology Corp. (TJBH) Income Statement
Tengjun Biotechnology Corp. (TJBH) income statement data is sourced from SEC Form 10-K and 10-Q filings. For fiscal year 2022, TJBH reported revenue of $0.15B, gross profit of $0.14B (gross margin 93.52%), and net income of $0.01B — a net profit margin of 7.56%.
Frequently asked questions
TJBH · 4 questionsTengjun Biotechnology Corp. (TJBH) reported revenue of $0.15B for 2022, up —% year-over-year.
TJBH revenueTJBH salesannual revenue YoYincome statement
· Source: FMP /stable/income-statement · SEC EDGAR Form 10-K & 10-Q · As of 2026-06-09